Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer
Authors
Keywords
Circulating free DNA, MEK, EGFR, clinical trial, colorectal cancer
Journal
Clinical Colorectal Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-07-25
DOI
10.1016/j.clcc.2021.07.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials
- (2020) Antonious Hazim et al. Journal of the National Comprehensive Cancer Network
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- (2018) C M Parseghian et al. ANNALS OF ONCOLOGY
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- (2018) Chiara Cremolini et al. JAMA Oncology
- Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- (2017) John H. Strickler et al. Cancer Discovery
- Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
- (2016) Jan Franko et al. LANCET ONCOLOGY
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
- (2014) T. Troiani et al. CLINICAL CANCER RESEARCH
- Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients†
- (2014) Narikazu Boku et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
- (2014) Yu Imamura et al. Molecular Cancer
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2014) S. Misale et al. Science Translational Medicine
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2012) CLINICAL CANCER RESEARCH
- Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials
- (2012) S. Gupta et al. JNCI-Journal of the National Cancer Institute
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- (2010) R. K. Jain et al. CLINICAL CANCER RESEARCH
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS
- (2009) Barb Melosky et al. Current Oncology
- Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer
- (2008) Salvatore Artale et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started